Tocilizumab Treatment Reduces Mortality in Hospitalized Patients With COVID-19: A Retrospective Cohort Study at a New York City Hospital. Issue 4 (3rd July 2022)

• Record Type: Journal Article
• Authors: Saliaj, Merjona; Li, Matthew; Rizzo, Vincent; Nassar, Mahmoud; Nso, Nso; Idrees, Zarwa; Medina, Luis A.; Novikov, Anastasia; Yaghi, Salim; Cuevas, Francisco J.; Salafia, Carolyn M.; Razaki, Hamid; Berman, Charles; Sachmechi, Issac; Trandafirescu, Theo; Brennessel, Debra; Martin, George T.; Mantis, Jazila
• Is Part Of: Infectious diseases in clinical practice. Volume 30:Issue 4(2022)
• Publication Date: 2022-07-03
• Subjects: tocilizumab -- mortality -- mechanical ventilation -- CRP -- IL-6 -- oxygen saturation; Communicable diseases -- Periodicals; Communicable Diseases -- Periodicals; Communicable diseases; Periodicals; Periodicals; Electronic journals; 616.9
• DOI: 10.1097/IPC.0000000000001146
• Languages: English
• ISSNs: 1056-9103

Abstract

Abstract : Aims: This study aimed to investigate the potential of tocilizumab therapy in minimizing mortality and mechanical ventilation (MV) requirements among hospitalized COVID-19 patients. Methods: A single-center, retrospective, observational cohort study of 375 patients with severe COVID-19 (from March 1 to April 22, 2020) included 150 patients treated with tocilizumab and 225 consecutive control patients adjusted for age and sex. Both groups received concomitant standard of care treatments in addition to tocilizumab. The statistical methods relied on survival analyses, conditional logistic regression models, and contingency analyses. The outcomes included in-hospital mortality and the MV requirement. Results: Tocilizumab associated with improved in-hospital mortality (34.7% vs 46.7%, P = 0.0136) and lower requirement for MV on days 1, 3, and 5 after treatment ( P = 0.005, P < 0.0001, and P = 0.0021, respectively). Lower mortality was observed if tocilizumab was administered within 48 hours after admission ( P = 0.0226). Older age and low blood oxygen saturation on admission decreased the odds of survival ( P < 0.005). Conclusions: Our study demonstrates a significant reduction in mortality and decreased requirement of MV with tocilizumab treatment in addition to the standard of care. Early administration of tocilizumab within 48 hours reduces the risk of mortality.